Levi & Korsinsky is investigating the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (Nasdaq: AMLN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Bristol-Myers Squibb (NYSE: BMY).
Click here to learn how to join the action:
, or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Amylin shareholders will receive $31.00 per share of Amylin stock they own. The transaction has an approximate total value of $7 billion, including the assumption of debt and a contractual payment obligation to Eli Lilly & Company. The investigation concerns whether the Amylin Board of Directors breached their fiduciary duties to Amylin stockholders by failing to adequately shop the Company before entering into this transaction and whether Bristol-Myers Squibb is underpaying for Amylin shares, thus unlawfully harming Amylin stockholders. In particular, at least one analyst set a price target of $32.00 per Amylin share.
If you own common stock in Amylin and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.